ARUP NGS Test Offerings

Next generation sequencing provides answers by identifying the unique genetic code. Likewise, we recognize the individual needs of every patient. Each case is carefully reviewed by both a variant scientist and a medical director to ensure a custom report tailored to each patient with the most cutting-edge clinical information available.

 On this page:

Myeloid Malignancies Mutation Panel by NGS
BCR-ABL1 Mutation Analysis for Tyrosine Kinase Inhibitor Resistance by NGS
Solid Tumor Mutation Panel by NGS
Chronic Lymphocytic Leukemia Mutation Panel by NGS
Acute Myeloid Leukemia Mutation Panel by Next Generation Sequencing

Explore your options for NGS testing. Contact the ARUP account executive in your area by calling Sales Support at 1-800-242-2787, ext. 2231.

  Myeloid Malignancies Mutation Panel by Next Generation Sequencing

 
test-tube2011117 Myeloid Malignancies Mutation Panel
  • Targeted sequencing approach provides cost-effective, comprehensive detection of diagnostic, prognostic, and therapeutic biomarkers in myeloid malignancies including acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, and chronic myelomonocytic leukemia.mia
  • Next generation sequencing methodology assesses for clonal architecture and detects sub-clonal populations that may drive relapse.
  • Adherence to National Comprehensive Cancer Network (NCCN) guidelines for mutation profiling in myeloid malignancies ensures accurate, industry-standard results.ncies

  BCR-ABL1 Mutation Analysis for Tyrosine Kinase Inhibitor Resistance by Next Generation Sequencing

 
test-tube2008420 BCR-ABL1 Mutation Analysis
  • Comprehensive detection of BCR-ABL1 tyrosine kinase inhibitor resistance mutations found in the SH2, SH3, and kinase domains.
  • Next generation sequencing methodology offers more sensitive detection of low variant allele frequency mutations than traditional methods, such as Sanger sequencing.

  Solid Tumor Mutation Panel by Next Generation Sequencing

 
test-tube2007991 Solid Tumor Mutation Panel
  • This assay is primarily oriented towards commonly mutated loci in the MAPK and PI3K pathways, together with coverage of selected tumor suppressors.
  • The tumor types most likely to benefit from this test are also among the most prevalent, namely lung carcinoma, colorectal carcinoma, and melanoma.
  • An enhanced report for this test details objective results with in-depth clinical interpretation in a visual, easy-to-read format.

  Chronic Lymphocytic Leukemia Mutation Panel by Next Generation Sequencing

 
test-tube3001858 Chronic Lymphocytic Leukemia Mutation Panel

Chronic lymphocytic leukemia (CLL) is a form of cancer of the blood and bone marrow and is one of the most common types of leukemia in adults.

  • This next generation sequencing based test can be used in conjunction with traditional CLL biomarkers (e.g., IGHV mutation status, CLL FISH panel) to further inform prognosis and clinical management of patients with CLL and other B-cell lymphoproliferative disorders..
  • This test can detect mutations in BTK and other genes that may confer resistance to BTK inhibitors, a class of drugs commonly used to treat CLL patients.

  Acute Myeloid Leukemia Mutation Panel by Next Generation Sequencing

 
test-tube3002714 Acute Myeloid Leukemia Mutation Panel by Next Generation Sequencing
  • Identification of gene mutations is key to effective management of patients with AML at diagnosis and relapse
  • This tailored NGS panel allows for detection of gene mutations with diagnostic, prognostic and/or predictive value
  • Use this test in conjunction with karyotype, FISH and rapid molecular assays (e.g., FLT3 PCR) for comprehensive genetic profiling of AML patients